KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Raw Materials: 2011-2024

Historic Raw Materials for Halozyme Therapeutics (HALO) over the last 14 years, with Dec 2024 value amounting to $24.0 million.

  • Halozyme Therapeutics' Raw Materials fell 37.99% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 37.99%. This contributed to the annual value of $24.0 million for FY2024, which is 1.56% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Raw Materials stood at $24.0 million for FY2024, which was up 1.56% from $23.6 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Raw Materials registered a high of $24.0 million during FY2024, and its lowest value of $5.8 million during FY2020.
  • Its 3-year average for Raw Materials is $20.5 million, with a median of $23.6 million in 2023.
  • Data for Halozyme Therapeutics' Raw Materials shows a peak YoY soared of 109.93% (in 2020) over the last 5 years.
  • Over the past 5 years, Halozyme Therapeutics' Raw Materials (Yearly) stood at $5.8 million in 2020, then spiked by 83.59% to $10.7 million in 2021, then climbed by 29.24% to $13.8 million in 2022, then surged by 71.45% to $23.6 million in 2023, then rose by 1.56% to $24.0 million in 2024.